文献速递临床试验与 GCP基础与转化研究

替尔泊肽诱导的体重减轻对肥胖症患者脂肪组织的影响:随机安慰剂对照TABFAT试验的依据与设计

Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial.
PubMed 文献 · Trials · 2025-08-22

TABFAT试验是一项由研究者发起的随机安慰剂对照临床试验,旨在评估替尔泊肽对绝经前肥胖女性棕色脂肪组织活性和白色脂肪组织褐变的影响。34名参与者按1:1随机接受替尔泊肽或安慰剂治疗24周,主要结局为通过18F-FDG-PET/CT、MRI和红外热成像评估的棕色脂肪组织体积和活性变化,以及皮下脂肪组织样本中mRNA表达模式和组织形态学改变。

要点

  • 替尔泊肽可能增强棕色脂肪组织活性并诱导白色脂肪组织褐变。
  • 试验纳入34名绝经前肥胖女性,1:1随机接受替尔泊肽或安慰剂治疗24周。
  • 主要结局为棕色脂肪组织体积和活性变化及白色脂肪组织褐变指标。

核心结论

  • 本研究首次系统探索药物性肥胖管理增强棕色脂肪组织活性和诱导白色脂肪组织褐变的潜力。
  • 结果可能将产热脂肪组织增强确立为第二代抗肥胖药物的新作用机制。

研究设计与样本

  • 由研究者发起的随机安慰剂对照临床试验,纳入绝经前肥胖女性。
  • 34名参与者按1:1随机接受替尔泊肽或安慰剂治疗24周。
  • 主要结局包括通过18F-FDG-PET/CT、MRI和红外热成像评估的棕色脂肪组织体积和活性变化,以及通过皮下脂肪组织样本中mRNA表达模式和组织形态学改变评估的白色脂肪组织褐变诱导。
  • 次要结局包括全身成分、静息能量消耗和多种代谢健康标志物评估,并与产热脂肪组织变化相关联。
  • 试验注册:ClinicalTrials.gov NCT06893211,注册日期2025年3月25日。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is a complex disease marked by excessive, dysfunctional adipose tissue accumulation. Recent research underscores the pivotal role of brown adipose tissue (BAT) in metabolic health and its potential as a therapeutic target for obesity management. Emerging preclinical and clinical evidence suggests that second-generation anti-obesity drugs, especially dual agonists such as tirzepatide, may enhance BAT activity. Additionally, beige adipose tissue, derived from white adipose tissue (WAT), may contribute significantly to whole-body thermogenesis, yet its role remains underexplored. METHODS: This investigator-initiated, randomized, placebo-controlled clinical trial aims to evaluate the effects of tirzepatide on BAT activity and WAT browning in premenopausal women with obesity. Thirty-four participants will be randomized 1:1 to receive either tirzepatide or a placebo for 24 weeks. Primary outcomes include changes in BAT volume and activity, assessed using 18F-FDG-PET/CT, MRI, and infrared thermography, as well as the induction of WAT browning, evaluated through changes in mRNA expression patterns and histomorphometric alterations in subcutaneous adipose tissue samples. Secondary outcomes will involve the assessment of whole-body composition, resting energy expenditure, and various metabolic health markers, correlated with thermogenic adipose tissue changes. Comparative analysis of BAT assessment methods will refine protocols for research and clinical use. DISCUSSION: This study is the first to systematically explore the potential of pharmacological obesity management to enhance BAT activity and induce WAT browning. Results may establish thermogenic adipose tissue augmentation as a novel mechanism of action for second-generation anti-obesity medications. TRIAL REGISTRATION: ClinicalTrials.gov NCT06893211. Registered on 2025 March 25.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Herman R, Jensterle M, Horvat S, et al. Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial. Trials. 2025. PMID: 40847412. doi:10.1186/s13063-025-09045-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。